Use of new once-daily 5-aminosalicylic acid preparations in the treatment of ulcerative colitis: Is there anything new under the sun?

Table 1 Efficacy of the MMX mesalazine formulations for induction and maintenance of remission in mild-to-moderate UC

Study	Phase	Patient number (n)	Dosing regimen (g/d)	Duration	Remission rates (%)
					Treatment	Placebo
Induction
D’Haens[14]	II	38	MMX 1.2		0
			MMX 2.4	8 wk	30.8	-
			MMX 4.8		18
Lichtenstein[15]	III	280	MMX 2.4	8 wk	34.1a	12.9
			MMX 4.8		29.2a
Kamm[16]	III	343	MMX 2.4	8 wk	40.5a
			MMX 4.8		41.2a	22.1
			Asacol™ 2.4		32.6
Sandborn[17], combined[2526]	III		MMX 2.4	8 wk	37.2a	17.5
			MMX 4.8		35.1a
Maintenance					Patients still in remission
Kamm[21]	III	459	MMX 2.4 od	12 mo	67.8
			MMX 2.4 bid		72.3
Prantera[26]	III	325	MMX 2.4 od	12 mo	69.2b
			Asacol™ 2.4 bid		56.8

^aP < 0.01 vs placebo;

^bP < 0.05, od vs bid remission rates: endoscopic and clinical remission rates.

Table 2 Efficacy of other, new mesalazine formulations for induction and maintenance of remission in mild-to-moderate UC

Study	Phase	Patient number (n)	Dosing regimen (g/d)	Duration	Remission rates (%)
Induction
Kruis[27]	III	388	Granules 3 od	8 wk	79.1
			Granules 3 tid Salofalk®		75.7
Maintenance					Patients still in remission
Dignass[30]	III	388	Granules 2 od	12 mo	73.8a
			Granules 2 bid		63.6
			Pentasa®
Kruis[29]	III	647	Granules 3.0 od	12 mo	74.7
			Granules 1.5 od		60.8
			Granules 1.5 tid		68.8
			Salofalk®

^aP < 0.05, od vs bid.